Effects of 18-month treatment with bazedoxifene on enzymatic immature and mature cross-links and non-enzymatic advanced glycation end products, mineralization, and trabecular microarchitecture of vertebra in ovariectomized monkeys

Bone

Volumn 81, Issue , 2015, Pages 573-580

  Saito, Mitsuru ^a   Kida, Yoshikuni ^a   Nishizawa, Tetsuro ^a   Arakawa, Shotaro ^a   Okabe, Hinako ^a   Seki, Azusa ^b   Marumo, Keishi ^a  

^a JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b Hamri Co Ltd   (Japan)

Author keywords

Advanced glycation end products; Bazedoxifene; Cancellous bone; Collagen cross links; OVX monkeys; Pentosidine

Indexed keywords

ADVANCED GLYCATION END PRODUCT; BAZEDOXIFENE; COLLAGEN; PENTOSIDINE; ARGININE; BONE DENSITY CONSERVATION AGENT; CROSS LINKING REAGENT; INDOLE DERIVATIVE; LYSINE; SELECTIVE ESTROGEN RECEPTOR MODULATOR;

ADULT; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BONE MASS; BONE MINERALIZATION; BONE STRENGTH; BONE STRUCTURE; CONTROLLED STUDY; FEMALE; NONHUMAN; OVARIECTOMY; PROTEIN BLOOD LEVEL; PROTEIN CONTENT; PROTEIN CROSS LINKING; RIGIDITY; TRABECULAR BONE; TREATMENT DURATION; VERTEBRA; ANALOGS AND DERIVATIVES; ANIMAL; BONE DENSITY; DISEASE MODEL; DRUG EFFECTS; HUMAN; LUMBAR VERTEBRA; MACACA FASCICULARIS; METABOLISM; MICRO-COMPUTED TOMOGRAPHY; OSTEOPOROSIS, POSTMENOPAUSAL; PATHOLOGY;

ANIMALS; ARGININE; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; COLLAGEN; CROSS-LINKING REAGENTS; DISEASE MODELS, ANIMAL; FEMALE; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; INDOLES; LUMBAR VERTEBRAE; LYSINE; MACACA FASCICULARIS; OSTEOPOROSIS, POSTMENOPAUSAL; OVARIECTOMY; SELECTIVE ESTROGEN RECEPTOR MODULATORS; X-RAY MICROTOMOGRAPHY;

EID: 84942252759     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2015.09.006     Document Type: Article

References (51)

1. Komm B.S., Kharode Y.P., Bodine P.V., Harris H.A., Miller C.P., Lyttle C.R. Bazedoxifene acetate: a selective estrogen receptor modulator with improved selectivity. Endocrinology 2005, 146:3999-4008.
2. Miller C.P., Collini M.D., Tran B.D., Harris H.A., Kharode Y.P., Marzolf J.T., Moran R.A., Henderson R.A., Bender R.H., Unwalla R.J., Greenberger L.M., Yardley J.P., Abou-Gharbia M.A., Lyttle C.R., Komm B.S. Design, synthesis, and preclinical characterization of novel, highly selective indole estrogens. J. Med. Chem. 2001, 44:1654-1657.
3. Bruyère O., Detilleux J., Chines A., Reginster J.Y. Relationships between changes in bone mineral density or bone turnover markers and vertebral fracture incidence in patients treated with bazedoxifene. Calcif. Tissue Int. 2012, 91:244-249.
4. Komm B.S., Chines A.A. Bazedoxifene: the evolving role of third-generation selective estrogen-receptor modulators in the management of postmenopausal osteoporosis. Ther Adv Musculoskelet Dis. 2012, 4:21-34.
5. Ellis A.G., Reginster J.Y., Luo X., Bushmakin A.G., Williams R., Sutradhar S., Mirkin S., Jansen J.P. Indirect comparison of bazedoxifene vs oral bisphosphonates for the prevention of vertebral fractures in postmenopausal osteoporotic women. Curr. Med. Res. Opin. 2014, 30:1617-1626.
6. Seeman E., Delmas P.D. Bone quality-the material and structural basis of bone strength and fragility. N. Engl. J. Med. 2006, 354:2250-2261.
7. Knott L., Bailey A.J. Collagen cross-links in mineralizing tissues: a review of their chemistry, function, and clinical relevance. Bone 1998, 22:181-187.
8. Saito M., Marumo K. Collagen cross-links as a determinant of bone quality: a possible explanation for bone fragility in aging, osteoporosis, and diabetes mellitus. Osteoporos. Int. 2010, 21:195-214.
9. Viguet-Carrin S., Garnero P., Delmas P.D. The role of collagen in bone strength. Osteoporos. Int. 2006, 17:319-336.
10. Uzawa K., Grzesik W.J., Nishiura T., Kuznetsov S.A., Robey P.G., Brenner D.A., Yamauchi M. Differential expression of human lysyl hydroxylase genes, lysine hydroxylation, and cross-linking of type I collagen during osteoblastic differentiation in vitro. J. Bone Miner. Res. 1999, 14:1272-1280.
11. Banse X., Sims T.J., Bailey A.J. Mechanical properties of adult vertebral cancellous bone: correlation with collagen intermolecular cross-links. J. Bone Miner. Res. 2002, 17:1621-1628.
12. Saito M., Fujii K., Soshi S., Tanaka T. Reductions in degree of mineralization and enzymatic collagen cross-links and increases in glycation-induced pentosidine in the femoral neck cortex in cases of femoral neck fracture. Osteoporos. Int. 2006, 17:986-995.
13. Saito M., Marumo K., Kida Y., Ushiku C., Kato S., Takao-Kawabata R., Kuroda T. Changes in the contents of enzymatic immature, mature, and non-enzymatic senescent cross-links of collagen after once-weekly treatment with human parathyroid hormone (1-34) for 18months contribute to improvement of bone strength in ovariectomized monkeys. Osteoporos. Int. 2011, 22:2373-2383.
14. Wang X., Shen X., Li X., Agrawal C.M. Age-related changes in the collagen network and toughness of bone. Bone 2002, 31:1-7.
15. Saito M., Fujii K., Mori Y., Marumo K. Role of collagen enzymatic and glycation induced cross-links as a determinant of bone quality in spontaneously diabetic WBN/Kob rats. Osteoporos. Int. 2006, 17:1514-1523.
16. Oxlund H., Barckman M., Ortoft G., Andreassen T.T. Reduced concentrations of collagen cross-links are associated with reduced strength of bone. Bone 1995, 17:365S-371S.
17. Vashishth D. The role of the collagen matrix in skeletal fragility. Curr. Osteoporos. Rep. 2007, 5:62-66.
18. Garnero P., Borel O., Gineyts E., Duboeuf F., Solberg H., Bouxsein M.L., Christiansen C., Delmas P.D. Extracellular post-translational modifications of collagen are major determinants of biomechanical properties of fetal bovine cortical bone. Bone 2006, 38:300-309.
19. Saito M., Marumo K., Soshi S., Kida Y., Ushiku C., Shinohara A. Raloxifene ameliorates detrimental enzymatic and nonenzymatic collagen cross-links and bone strength in rabbits with hyperhomocysteinemia. Osteoporos. Int. 2010, 21:655-666.
20. Saito M., Mori S., Mashiba T., Komatsubara S., Marumo K. Collagen maturity, glycation induced-pentosidine, and mineralization are increased following 3-year treatment with incadronate in dogs. Osteoporos. Int. 2008, 19:1343-1354.
21. Vashishth D., Gibson G.J., Khoury J.I., Schaffler M.B., Kimura J., Fyhrie D.P. Influence of nonenzymatic glycation on biomechanical properties of cortical bone. Bone 2001, 28:195-201.
22. Tang S.Y., Vashishth D. Non-enzymatic glycation alters microdamage formation in human cancellous bone. Bone 2010, 46:148-154.
23. Saito M., Grynpas M.D., Burr D.B., Allen M.R., Smith S.Y., Doyle N., Amizuka N., Hasegawa T., Kida Y., Marumo K., Saito H. Treatment with eldecalcitol positively affects mineralization, microdamage, and collagen crosslinks in primate bone. Bone 2015, 73:8-15.
24. Nojiri H., Saita Y., Saito M., Kobayashi K., Tsuda C., Miyazaki T., Saito M., Marumo K., Yonezawa I., Kaneko K., Shirasawa T., Shimizu T. Cytoplasmic superoxide causes bone fragility due to low turnover osteoporosis with impaired collagen cross-links. J. Bone Miner. Res. 2011, 26:2682-2694.
25. Saito M., Fujii K., Marumo K. Degree of mineralization-related collagen cross-linking in the femoral neck cancellous bone in cases of hip fracture and controls. Calcif. Tissue Int. 2006, 79:160-168.
26. Karim L., Tang S.Y., Sroga G.E., Vashishth D. Differences in non-enzymatic glycation and collagen cross-links between human cortical and cancellous bone. Osteoporos. Int. 2013, 24:2441-2447.
27. Smith S.Y., Jolette J., Chouinard L., Komm B.S. The effects of bazedoxifene in the ovariectomized aged cynomolgus monkey. J. Bone Miner. Metab. 2014, 32:161-172.
28. Laib A., Kumer J.L., Majumdar S., Lane N.E. The temporal changes of trabecular architecture in ovariectomized rats assessed by MicroCT. Osteoporos. Int. 2001, 12:936-941.
29. Saito M., Marumo K., Fujii K., Ishioka N. Single-column high-performance liquid chromatographic-fluorescence detection of immature, mature, and senescent cross-links of collagen. Anal. Biochem. 1997, 253:26-32.
30. Tang S.Y., Zeenath U., Vashishth D. Effects of non-enzymatic glycation on cancellous bone fragility. Bone 2007, 40:1144-1151.
31. Ural A., Janeiro C., Karim L., Diab T., Vashishth D. Association between non-enzymatic glycation, resorption, and microdamage in human tibial cortices. Osteoporos Int. 2015, 26:865-873.
32. Robins S.P. Biochemistry and functional significance of collagen cross-linking. Biochem. Soc. Trans. 2007, 35:849-852.
33. Saito M., Shiraishi A., Ito M., Sakai S., Hayakawa N., Mihara M., Marumo K. Comparison of effects of alfacalcidol and alendronate on mechanical properties and bone collagen cross-links of callus in the fracture repair rat model. Bone 2010, 46:1170-1179.
34. Ozasa H., Tominaga T., Nishimura T., Takeda T. Lysyl oxidase activity in the mouse uterine cervix is physiologically regulated by estrogen. Endocrinology 1981, 109:618-621.
35. Ireland D.C., Bord S., Beavan S.R., Compston J.E. Effects of estrogen on collagen synthesis by cultured human osteoblasts depend on the rate of cellular differentiation. J. Cell. Biochem. 2002, 86(2):251-257.
36. Manolagas S.C. From estrogen-centric to aging and oxidative stress: a revised perspective of the pathogenesis of osteoporosis. Endocr. Rev. 2010, 31:266-300.
37. Urbieta-Caceres V.H., Syed F.A., Lin J., Zhu X.Y., Jordan K.L., Bell C.C., Bentley M.D., Lerman A., Khosla S., Lerman L.O. Age-dependent renal cortical microvascular loss in female mice. Am. J. Physiol. Endocrinol. Metab. 2012, 302:E979-E986.
38. Chen J.Y., Tsai P.J., Tai H.C., Tsai R.L., Chang Y.T., Wang M.C., Chiou Y.W., Yeh M.L., Tang M.J., Lam C.F., Shiesh S.C., Li Y.H., Tsai W.C., Chou C.H., Lin L.J., Wu H.L., Tsai Y.S. Increased aortic stiffness and attenuated lysyl oxidase activity in obesity. Arterioscler. Thromb. Vasc. Biol. 2013, 33:839-846.
39. Raposo B., Rodriguez C., Martinez-Gonzalez J., Badimon L. High levels of homocysteine inhibit lysyl oxidase (LOX) and down regulate LOX expression in vascular endothelial cells. Atherosclerosis 2004, 177:1-8.
40. McCarthy A.D., Etcheverry S.B., Bruzzone L., Lettieri G., Barrio D.A., Cortizo A.M. Non-enzymatic glycation of a type I collagen matrix: effect on osteoblastic development and oxidative stress. BMC Cell Biol. 2001, 2:16.
41. Sanada H., Shikata J., Hamamoto H., Ueba Y., Yamamuro T., Takeda T. Changes in collagen cross-linking and lysyl oxidase by estrogen. Biochim. Biophys. Acta 1978, 541:408-413.
42. Khastgir G., Studd J., Holland N., Alaghband-Zadeh J., Sims T.J., Bailey A.J. Anabolic effect of long-term estrogen replacement on bone collagen in elderly postmenopausal women with osteoporosis. Osteoporos. Int. 2001, 12:465-470.
43. Paschalis E.P., Boskey A.L., Kassem M., Erisksen E.F. Effect of hormone replacement therapy on bone quality in early postmenopausal women. J. Bone Miner. Res. 2003, 18:955-959.
44. Gallant M.A., Brown D.M., Hammond M., Wallace J.M., Du J., Deymier-Black A.C., Almer J.D., Stock S.R., Allen M.R., Burr D.B. Bone cell-independent benefits of raloxifene on the skeleton: a novel mechanism for improving bone material properties. Bone 2014 Apr, 61:191-200. Epub 2014 Jan 24. 10.1016/j.bone.2014.01.009.
45. Allen M.R., Territo P.R., Lin C., Persohn S., Jiang L., Riley A.A., McCarthy B.P., Newman C.L., Burr D.B., Hutchins G.D. In vivo UTE-MRI reveals positive effects of raloxifene on skeletal bound water in skeletally mature beagle dogs. J Bone Miner Res Jan 31 2015, ([Epub ahead of print]). 10.1002/jbmr.2470.
46. Hemachandra L.P., Patel H., Chandrasena R.E., Choi J., Piyankarage S.C., Wang S., Wang Y., Thayer E.N., Scism R.A., Michalsen B.T., Xiong R., Siklos M.I., Bolton J.L., Thatcher G.R. SERMs attenuate estrogen-induced malignant transformation of human mammary epithelial cells by upregulating detoxification of oxidative metabolites. Cancer Prev. Res. (Phila.) 2014, 7:505-515.
47. Banse X., Sims T.J., Bailey A.J. Mechanical properties of adult vertebral cancellous bone: correlation with collagen intermolecular cross-links. J. Bone Miner. Res. 2002, 17:1621-1628.
48. Biemel K.M., Reihl O., Conrad J., Lederer M.O. Formation pathways for lysine-arginine cross-links derived from hexoses and pentoses by Maillard processes: unraveling the structure of a pentosidine precursor. J. Biol. Chem. 2001, 276:23405-23412.
49. Burr D.B., Hirano T., Turner C.H., Hotchkiss C., Brommage R., Hock J.M. Intermittently administered human parathyroid hormone(1-34) treatment increases intracortical bone turnover and porosity without reducing bone strength in the humerus of ovariectomized cynomolgus monkeys. J. Bone Miner. Res. 2001, 16:157-165.
50. Fox J., Miller M.A., Newman M.K., Turner C.H., Recker R.R., Smith S.Y. Treatment of skeletally mature ovariectomized rhesus monkeys with PTH(1-84) for 16months increases bone formation and density and improves trabecular architecture and biomechanical properties at the lumbar spine. J. Bone Miner. Res. 2007, 22:260-273.
51. Fox J., Newman M.K., Turner C.H., Guldberg R.E., Varela A., Smith S.Y. Effects of treatment with parathyroid hormone 1-84 on quantity and biomechanical properties of thoracic vertebral trabecular bone in ovariectomized rhesus monkeys. Calcif. Tissue Int. 2008, 82:212-220.